Fablyn lasofoxifene regulatory update

FDA’s Reproductive Health Drugs Advisory Committee will meet on Sept. 8 to discuss an NDA from Pfizer for Fablyn lasofoxifene to treat osteoporosis in postmenopausal women. The company submitted the a...